clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2025-3-1-35-43clinicaloncology-101Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSГлазная форма миастении на фоне химиоиммунотерапевтического лечения dMMR/MSI местнораспространенного рака желудка с достижением полного морфологического регрессаOcular form of myasthenia gravis which developed as a result of chemoimmunotherapeutic treatment of locally advanced stomach cancer MSI with achievement of pCRhttps://orcid.org/0009-0000-1467-3781КыркуновА. В.KyrkunovA. V.

Кыркунов Александр Витальевич

197706, г. Сестрорецк, ул. Борисова, д. 9

 

Alexandr V. Kyrkunov

9 Borisov st., Sestroreck, 197706

kyrkunov-aleksandr@rambler.ruТюкавинаН. В.TyukavinaN. V.

197706, г. Сестрорецк, ул. Борисова, д. 9

Nina V. Tyukavina

9 Borisov st., Sestroreck, 197706

https://orcid.org/0000-0001-5318-2619ГладышевД. В.GladishevD. V.

197706, г. Сестрорецк, ул. Борисова, д. 9

Dmitry V. Gladishev

9 Borisov st., Sestroreck, 197706

СПб ГБУЗ «Городская больница № 40 Курортного района»РоссияCity hospital Nо. 40 Kurortny regionRussian Federation202513072025313543Copyright © Кыркунов А.В., Тюкавина Н.В., Гладышев Д.В., 20252025Кыркунов А.В., Тюкавина Н.В., Гладышев Д.В.Kyrkunov A.V., Tyukavina N.V., Gladishev D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/101

Иммунотерапия (ИТ) является одним из основных способов лечения солидных опухолей. Показания к ИТ с каждым годом становятся обширнее, накапливаются данные по наблюдению и борьбе с нежелательными аутоиммунными явлениями. Редкие осложнения встречаются все чаще. В данном клиническом случае представлен опыт применения химиоиммунотерапии в неоадъювантном режиме местнораспространенного рака желудка с MSI с достижением полного морфологического регресса и развитием глазной формы миастении.

Immunotherapy (IT) is one of the main ways to treat solid tumors. Indications for IT become more extensive every year, and data on monitoring and treating autoimmune adverse events are accumulating. Rare complications become more common. In this clinical case, we show experience of using chemoimmunotherapy in the neoadjuvant setting of locally advanced gastric cancer with the presence of microsatellite instability and autoimmune adverse event — ocular myasthenia gravis.

рак желудкаdMMRMSIхимиоиммунотерапиямиастенияgastric cancerdMMRchemoimmunotherapymyasthenia gravisReferencesMansfield Р.F. Clinical features, diagnosis, and staging of gastric cancer /FACS Section еds.: K. K. Tanabe, J. B. Kruskal, deputy еds.: D. M. F. Savarese, Sh. Grover. 2017.Mansfield Р.F. Clinical features, diagnosis, and staging of gastric cancer /FACS Section еds.: K. K. Tanabe, J. B. Kruskal, deputy еds.: D. M. F. Savarese, Sh. Grover. 2017.Al-Batran S.E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastrooesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial // The Lancet Oncology. 2016. Vol. 17, No. 12. Р. 1697–1708.Al-Batran S.E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastrooesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial // The Lancet Oncology. 2016. Vol. 17, No. 12. Р. 1697–1708.Al-Batran S.E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastrooesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial // The Lancet. 2019. Vol. 393, No. 10184. Р. 1948–1957.Al-Batran S.E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastrooesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial // The Lancet. 2019. Vol. 393, No. 10184. Р. 1948–1957.André T. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study // Journal of Clinical Oncology. 2023. Vol. 41, No. 2. Р. 255–265.André T. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study // Journal of Clinical Oncology. 2023. Vol. 41, No. 2. Р. 255–265.Ilson D.H. KEYNOTE-585: disappointing results for perioperative pembrolizumab in gastric cancer // Translational Gastroenterology and Hepatology. 2024. Vol. 10. Р. 18.Ilson D.H. KEYNOTE-585: disappointing results for perioperative pembrolizumab in gastric cancer // Translational Gastroenterology and Hepatology. 2024. Vol. 10. Р. 18.Al-Batran S.E. et al. 1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK // Annals of Oncology. 2021. Vol. 32. Р. S1069.Al-Batran S.E. et al. 1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK // Annals of Oncology. 2021. Vol. 32. Р. S1069.Sun H. et al. 450P Neoadjuvant chemo-immunotherapy in mismatch repair deficient (dMMR)/microsatellite instability (MSI) gastric carcinoma (GC): A multicenter retrospective study // Annals of Oncology. 2024. Vol. 35. Р. S180–S181.Sun H. et al. 450P Neoadjuvant chemo-immunotherapy in mismatch repair deficient (dMMR)/microsatellite instability (MSI) gastric carcinoma (GC): A multicenter retrospective study // Annals of Oncology. 2024. Vol. 35. Р. S180–S181.Wan T. et al. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies // Annals of Surgical Oncology. 2019. Vol. 26. Р. 1412–1420.Wan T. et al. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies // Annals of Surgical Oncology. 2019. Vol. 26. Р. 1412–1420.Janjigian Y.Y. et al. Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) // Journal of Clinical Oncology. 2025. Vol. 43, Nо. 17, suppl. https://doi.org/10.1200/JCO.2025.43.17_suppl.LBA5.Janjigian Y.Y. et al. Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) // Journal of Clinical Oncology. 2025. Vol. 43, Nо. 17, suppl. https://doi.org/10.1200/JCO.2025.43.17_suppl.LBA5.Al-Batran S.E. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial // JAMA oncology. 2017. Vol. 3, No. 9. Р. 1237–1244.Al-Batran S.E. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial // JAMA oncology. 2017. Vol. 3, No. 9. Р. 1237–1244.Janjigian Y.Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastrooesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial // The Lancet. 2021. Vol. 398, No. 10294. Р. 27–40.Janjigian Y.Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastrooesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial // The Lancet. 2021. Vol. 398, No. 10294. Р. 27–40.Topalian S.L. et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab // JAMA oncology. 2019. Vol. 5, No. 10. Р. 1411–1420.Topalian S.L. et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab // JAMA oncology. 2019. Vol. 5, No. 10. Р. 1411–1420.Narita T. et al. Immunotherapy for ocular myasthenia gravis: an observational study in Japan // Therapeutic Advances in Neurological Disorders. 2023. Vol. 16. Р. 17562864231163819.Narita T. et al. Immunotherapy for ocular myasthenia gravis: an observational study in Japan // Therapeutic Advances in Neurological Disorders. 2023. Vol. 16. Р. 17562864231163819.Xiong B.H. et al. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer // Cancer investigation. 2014. Vol. 32, No. 6. Р. 272–284.Xiong B.H. et al. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer // Cancer investigation. 2014. Vol. 32, No. 6. Р. 272–284.Ronellenfitsch U. et al. Perioperative chemo (radio) therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus // Cochrane Database of Systematic Reviews. 2013. No. 5.Ronellenfitsch U. et al. Perioperative chemo (radio) therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus // Cochrane Database of Systematic Reviews. 2013. No. 5.Diaz‐Nieto R., Orti‐Rodríguez R., Winslet M. Post‐surgical chemotherapy versus surgery alone for resectable gastric cancer // Cochrane Database of Systematic Reviews. 2013. No. 9.Diaz‐Nieto R., Orti‐Rodríguez R., Winslet M. Post‐surgical chemotherapy versus surgery alone for resectable gastric cancer // Cochrane Database of Systematic Reviews. 2013. No. 9.Wan T. et al. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies // Annals of Surgical Oncology. 2019. Vol. 26. Р. 1412–1420.Wan T. et al. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies // Annals of Surgical Oncology. 2019. Vol. 26. Р. 1412–1420.Transverse myelitis. National Organization for Rare Disorders (NORD). https://rarediseases.org/rarediseases/transverse-myelitis/ (Accessed on August 18, 2023).Transverse myelitis. National Organization for Rare Disorders (NORD). https://rarediseases.org/rarediseases/transverse-myelitis/ (Accessed on August 18, 2023).Al-Batran S.E. et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction — a phase III trial of the German AIO/CAO-V/CAOGI // BMC cancer. 2017. Vol. 17. Р. 1–7.Al-Batran S.E. et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction — a phase III trial of the German AIO/CAO-V/CAOGI // BMC cancer. 2017. Vol. 17. Р. 1–7.

The authors declare that there are no conflicts of interest present.